American Glaucoma Society Meeting

American Glaucoma Society Meeting

Perspective from Douglas J. Rhee, MD
March 07, 2017
1 min read

Fixed combination dosing lowers IOP more than individual components

Perspective from Douglas J. Rhee, MD
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

CORONADO, Calif. — An “astounding” 40% reduction in IOP achieved with one drug given once a day was achieved in 35% of patients taking a fixed-dose combination of netarsudil and latanoprost, according to a speaker here.

Sanjay Asrani, MD, updated colleagues at the American Glaucoma Society meeting on the 3-month interim results of the Mercury 1 trial, a double-masked, randomized, multicenter, active-controlled, parallel-group 12-month phase 3 study comparing safety and efficacy of a fixed-dose prostaglandin combination with safety and efficacy of each of its components.

Sanjay Asrani

Sanjay Asrani

A total of 718 patients were randomized 1:1:1 to receive Roclatan (netarsudil 0.02%, latanoprost ophthalmic solution 0.005%, Aerie Pharmaceuticals), netarsudil 0.02% or latanoprost ophthalmic solution 0.005%. Baseline demographics were similar in all three groups.

At 3 months, the intend to treat results showed the fixed-dose combination differed from its individual components by 1.5 mm Hg to 2.5 mm Hg, demonstrating greater efficacy, Asrani said. In the fixed-dose combination group, 82% of patients achieved 18 mm Hg or lower IOP.

Even “more remarkable,” Asrani said, was that 61% of patients in the fixed-dose combination group achieved less than 16 mm Hg pressure compared with 39% in the latanoprost group, and 33% achieved pressures less than 14 mm Hg compared with 15% in the latanoprost group.

“These are the first times we’re seeing pressures as low as under 14 mm Hg with one drug dosed once a day,” Asrani said. – by Patricia Nale, ELS


Asrani S. A 3-month interim report of a prospective 12-month study assessing the safety and ocular hypotensive efficacy of PG324 ophthalmic solution (FDC) compared to netarsudil 0.02% and latanoprost 0.005% in subjects with elevated IOP (Mercury 1). Presented at: American Glaucoma Society annual meeting; March 2-5, 2017; Coronado, Calif.

Disclosure: Asrani reports he is a consultant for Roche, Dose Medical and Camras Vision and receives honoraria from Heidelberg Engineering.